Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV
Start > Research and development > Scientific publications
  • Scientific publications
  • Immunotherapy of cancer
  • Pipeline
  • Technology platform
  • Scientific advisors
  • A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody
    Jeffrey Yachnin , Gustav J. Ullenhag , Ana Carneiro , Dorte Nielsen , Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten, Charlotte Astrid Russell, Poster ASCO May 20, 2020
  • A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody
    Jeffrey Yachnin, Gustav J. Ullenhag, Ana Carneiro, Dorte L. Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Erika Bågeman, Camilla S. Wennersten, Charlotte Astrid Russell, AACR Virtual Annual Meeting, access through link, https://www.youtube.com/channel/UCblfdPkN76f_NTD0qBtJlBg/videos
  • ATOR-1017, a 4-1BB Antibody Developed for Tumor-Directed Immunotherapy of Cancer
    D Werchau, A Rosén, M Eriksson, S Järnum, C Furebring and K Enell Smith, Poster SITC November 9, 2019
  • Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
    M Nelson, R Miller, R Bader, D Werchau, A Nilsson, L Ljung, A Deronic, A Chunyk, L Schultz, C McMahan, D Bienvenue, A Dahlman, S Fritzell, M Askmyr, G Hernandez-Hoyos, Poster SITC November 9, 2019
  • 4224, a tumor exosome-transforming antibody targeting CD40 and EpCAM, induces superior anti-tumor effects compared to monospecific CD40 antibody
    Adnan Deronic, Laura von Schantz, Mia Thagesson, Kristine Smedenfors, Christina Sakellariou, Lill Ljung, Fredrika Carlsson, Doreen Werchau, Malin Lindstedt, Peter Ellmark, Karin Hägerbrand, CICON, 26 September 2019
  • A first-in-human, multicenter, open-label, phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015
    Jeffrey Yachnin, Gustav J Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Anna Dahlman, Erika Bågeman, Camilla Wennersten , Charlotte Astrid Russell., Poster ASCO, June 1, 2019,
  • RUBY TM – A novel recombinant universal bispecific antibody format for generation of bsAb with outstanding stability, manufacturability and shorter development timelines
    A Säll, M Levin, B Nyesiga, M Mårtensson, S Fritzell, K Hägerbrand, C Furebring, L von Schantz, Poster PEGS 11 April 2019
  • ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells
    S Fritzell, M Levin, A Dahlman, I Åberg, M Johansson, M Winnerstam, K Enell Smith, P Ellmark, C Furebring, P Norlén, A Månsson Kvarnhammar , AACR Annual Meeting April 2, 2019
  • Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
    A Dahlman, M Nelson, J Bannink, Starrla Johnson, D Werchau, A Nilsson, L Ljung, G Blahnik-Fagan, R Bader, P Ellmark, M Askmyr, G Hernandez-Hoyos, C McMahan, S Fritzell, AACR Annual Meeting April 1, 2019
  • The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Dahlman, Anna Rosén, Maria Johansson, Ida Åberg, Per Norlén, Christina Furebring and Peter Ellmark, SITC November 9, 2018
  • ATOR-1017, a tumor directed Fcγ-receptor cross-linking dependent ATOR-1017, a tumor directed Fcγ-receptor cross-linking dependent
    Karin Enell Smith, Anna Rosén, Anna Dahlman, Karin Barchan, Ida Åberg, Doreen Werchau, Mia Thagesson, Niina Veitonmäki, Christina Furebring and Peter Ellmark, SITC November 9, 2018
  • Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
    Michelle Nelson, Gabriele Blahnik-Fagan, Robert Bader, Doreen Werchau, Anneli Nilsson, Lill Ljung, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Catherine McMahan, David Bienvenue, Maria Askmyr, Anna Dahlman, Peter Ellmark, Gabriela Hernandez-Hoyos and Sara Fritzell , SITC November 9, 2018
  • ATOR-1017; a 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy
    Eva Dahlén, Anna Rosén, Adnan Deronic, Karin Barchan, Anna Dahlman, Peter Ellmark, Tina Furebring and Karin Enell Smith, 4th CRI-CIMT-EATI-AACR International Cancer lmmunotherapy Conference September 30, 2018
  • The agonistic CD40 antibody improves T cell responses and delays growth of a syngeneic tumor in an ovalbumin vaccination model
    Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Niina Veitonmäki, Per Norlén, Christina Furebring and Peter Ellmark, World Preclinical Congress June 2018
  • CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Maria Johansson, Per Norlén, Christina Furebring and Peter Ellmark, Poster CIMT May 16, 2018
  • Tumor Antigen-dependent T Cell Activation And Tumor Localization Induced By A Novel 4-1BB X 5T4 ADAPTIR™ Bispecific Antibody
    Sara Fritzell, Doreen Werchau, Maria Askmyr, Niina Veitonmäki, Anneli Nilsson, Adnan Deronic, Mia Thagesson, Anna Säll, Laura von Schantz, Robert Bader, Gabriele Blahnik-Fagan, Michelle Nelson, David Bienvenue, Gabriela Hernandez-Hoyos, Peter Ellmark , Poster CIMT May 16, 2018
  • Activation of the CD137 Pathway in T cells by a CD137 x 5T4 bispecific ADAPTIR™ Molecule Requires Co-engagement of CD137 and 5T4
    Gabriele Blahnik-Fagan, Robert Bader, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Cathy McMahan, David Bienvenue, Laura von Schantz, Eva Lindqvist, Doreen Werchau, Anneli Nilsson, Maria Askmyr, Niina Veitonmäki, Sara Fritzell, Peter Ellmark, Michelle Nelson1, and Gabriela Hernandez-Hoyos, Poster AAI May 5, 2018
  • Design and Generation of Bispecific Antibodies for Immuno-Oncology
    von Schantz L, Säll A, Carlsson F, Thorulffsson M, Petersson J, Tsiobanelis K, Nyesiga B, Jansson K, Rosén A, Hägerbrand K, Dahlman A, Månsson-Kvarnhammar A, Veitonmäki N and Furebring C., Poster PEGS May 2, 2018
  • Screening, Optimization and Characterization of a Novel 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
    von Schantz L, Misher L, Mitchell D, Gruswitz F, Woodruff B, Daugherty M, Aguilar M, Huntington K, Bader R, Blahnik-Fagan G, Säll A, Werchau D, Thagesson M, Nilsson A, Deronic A, Askmyr M, Veitonmäki N, Fritzell S, Ellmark P, Hernandez-Hoyos G and Bienvenue D., Poster PEGS May 2, 2018
  • CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Veitonmäki N, Månsson Kvarnhammar A, Fritzell S, Enell Smith K, Thagesson M, Werchau D, Hägerbrand K, Rosén A, Johansson M, Norlén P, Furebring C, Ellmark P, Poster AACR April 17, 2018
  • Bispecific antibodies in cancer immunotherapy
    Eva Dahlén, Niina Veitonmäki and Per Norlén , Therapeutic advances in vaccines and immunotherapy, 2018, Vol. 6(1) 3–17,

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact
  • Privacy policy

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree